Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
From these results and concomitant behavioral studies, we conclude that social dysfunctions resulting from excessive intake of ∆9-THC in the increasingly available marijuana products used by male teens may largely reflect circuit defects in PL-PFC networks communicating through endocannabinoid-regulated NMDA receptors.
|
31323660 |
2020 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of trans-del-ta-9-tetrahydrocannabinol (Δ9-THC) in marijuana and other preparations of cannabis are mediated by the endocannabinoid system, which is also briefly introduced.Much variation exists in the current literature regarding the functional changes associated with chronic cannabis use.
|
31364398 |
2019 |
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study focused on 11-nor-9carboxy-Δ9-THC (THC-COOH) and Benzoylecgonine (BE), the most common metabolites of cannabis and cocaine, respectively, present in the domestic sewage entering the wastewater treatment plants.
|
30690404 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we addressed the effects of OEA on the association of alcohol and cannabis, a frequent combination in human alcohol addicts, and whose long-term effects are far from being understood.To this end, OEA (10 mg/kg/day, i.p.) was pharmacologically administered for 5 days/week in a preclinical model of adolescent rats with binge-like consumption (1 day/week) of ethanol (3 g/kg, i.g.) combined or not with acute administrations of Δ<sup>9</sup>-THC (5 mg/kg, i.p.) for 5 weeks.
|
31068789 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, there is a need for regulated cannabis markets to develop more effective packaging and labelling standards to allow consumers to effectively titrate their THC intake, with the goal of promoting lower-risk cannabis use.
|
31351756 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to study whether the nicotine delivered via e-CIG acts as "a gateway drug" to the use of cannabis, we analysed the behavioural and molecular effects of 7 weeks' pre-exposure to air (AIR), e-CIGs or CIGs on addiction-related conditioned place preference (CPP) in mice using a sub-threshold (0.01 mg/kg) dose of delta-9-tetrahydrocannabinol (Δ<sup>9</sup>-THC), the principal psychoactive constituent of cannabis.
|
30773388 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fact that not all users develop cognitive impairment suggests a genetic vulnerability to adverse effects of cannabis, which are attributed to action of Δ9-tetrahydrocannabinol (Δ<sup>9</sup>-THC), a cannabis constituent and partial agonist of brain cannabinoid receptor 1.
|
30219209 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose herein a Fast High Pressure Liquid Chromatography (Fast-HPLC-DAD) method which allows the efficient separation of CBN (Cannabinol), CBD (Cannabidiol), THC-A and Δ<sup>9</sup>-THC, the major cannabinoids compounds found in cannabis plants in less than 5 min.
|
30348368 |
2019 |
Marijuana Abuse
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Potential drivers for a rising prevalence of cannabis use disorders comprise changes in consumption patterns and increasing levels of THC in available cannabis products.
|
31030057 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mean speed (but not lateral control) significantly differed between groups 30 min after smoking cannabis (p ≤ 0.02); low and high THC groups decreased their speed compared to placebo.
|
31678833 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main active chemical of marijuana (delta-9-tetrahydrocannabinol [THC]) readily crosses the placenta, and cannabinoid receptors have been identified in fetal brain and placenta.
|
31343707 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to determine whether inhalation of cannabis decreases headache and migraine ratings as well as whether gender, type of cannabis (concentrate vs. flower), THC, CBD, or dose contribute to changes in these ratings.
|
31715263 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
While a number of studies have explored the influence of cannabis or Δ9-THC on alcohol consumption and treatment outcomes, few have examined the effects of CBD on alcohol-related outcomes.
|
31120285 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Study groups were defined as SC users (anyone who reported use of SCs over the past 3 months), cannabis users (positive toxicology screen for Δ⁹-tetrahydrocannabinol [THC]), and controls (those who denied use of SCs over the past 3 months and had negative toxicology for THC).
|
31265768 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current cannabis use was evaluated by asking "In the past two weeks, have you used marijuana (including THC and/or CBD)?" and cannabis type used was assessed by asking "What do you primarily use THC, CBD, or both?".
|
31251769 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A positive urine drug screen for tetrahydocannabinol (THC+ status), the principal psychoactive constituent in cannabis, was associated with worse WM performance and differential brain response in areas previously linked to WM performance.
|
30644440 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since 2013, the Italian law allows pharmacists to prepare and dispense cannabis extracts to patients under medical prescription, and requires the evaluation of CBD and Δ<sup>9</sup>-THC content in cannabis extracts before sale.
|
30685656 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a survey of patients registered for medical marijuana (low tetrahydrocannabinol [THC] oil cards) in an ambulatory palliative care practice in Georgia (one of the states with restrictive medical marijuana laws).
|
31442099 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A double-blind, randomized, placebo-controlled crossover design was used to investigate the symptomatic effects of acute intravenous administration of ∆9-THC (1.19 mg/2 mL) in 16 healthy participants (seven males) with modest previous cannabis exposure.
|
31027219 |
2019 |
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, amphetamine (AMP), methamphetamine (METH), 3,4-methylenedioxymethamphetamine (MDMA), cocaine (COC) (from benzoylecgonine), and cannabis (from THC-COOH) consumption levels were investigated for the first time in Turkey (Istanbul).
|
30504023 |
2019 |
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lower baseline Glx values (r = -0.55; P = 0.026) and higher previous cannabis exposure (r = 0.52; P = 0.040) were associated with a higher Δ9-THC-induced Glx increase.
|
30770892 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adolescent rats of both sexes were exposed to either cannabis smoke from postnatal days (P) 29-49 or ascending doses of THC from P35-45.
|
31044291 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated that surfaces exposed to side-stream cannabis vapor are positive for THC at quantifiable levels.
|
31819131 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 100 μg/L or higher concentration of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) in blood serum is generally assumed to be associated with regular and/or heavy use of cannabis.
|
30193411 |
2019 |
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
The interim adoption of the respirable cotton dust exposure standard of 0.2 mg/m<sup>3</sup> for workplace exposure in hemp facilities until a cannabis workplace exposure standard is developed, and that exposure to medicinal cannabis containing THC are kept as low as reasonably practicable.
|
30281413 |
2019 |